Stock 002099 ZHEJIANG HISOAR PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Zhejiang Hisoar Pharmaceutical Co., Ltd.

Equities

002099

CNE000001PY2

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
6.36 CNY +0.79% Intraday chart for Zhejiang Hisoar Pharmaceutical Co., Ltd. -3.05% -11.54%
04-28 Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-18 Hisoar Pharma's Unit Passes German Health Regulator's Inspection MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hisoar Pharma's Unit Passes German Health Regulator's Inspection
MT
Tranche Update on Zhejiang Hisoar Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.
CI
Hisoar Pharma Chairman Plans Up to 20 Million Yuan Investment
MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Hisoar Pharma Passes Good Manufacturing Practice Compliance Inspection
MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Zhejiang Hisoar Pharma Registers New Drug For Diabetes Patients
MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 24 May 2023
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Approves the Profit Distribution Proposal for 2022
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for 2022
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hainan Visum Pharmaceutical Co Ltd announced that it has received $15 million in funding from Zhejiang Hisoar Pharmaceutical Co., Ltd.
CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 25 May 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002099 Stock
  4. News Zhejiang Hisoar Pharmaceutical Co., Ltd.